A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Nemolizumab, sold under the brand name Nemluvio, is a humanized monoclonal antibody used for the treatment of prurigo nodularis and atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Nemolizumab is humanized IgG2 monoclonal antibody that inhibits interleukin-31 signaling by binding selectively to interleukin-31 receptor alpha. It is an interleukin-31 receptor antagonist. IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation and fibrosis. By inhibiting IL-31-induced responses, nemolizumab prevents the release of proinflammatory cytokines and chemokines. Nemolizumab was approved for medical use in the United States in August 2024, and in the European Union in February 2025. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
=== Homology === In the genomic branch of bioinformatics, homology is used to predict the function of a gene: if the sequence of gene A, whose function is known, is homologous to the sequence of gene B, whose function is unknown, one could infer that B may share A's function. In structural bioinformatics, homology is used to determine which parts of a protein are important in structure formation and interaction with other proteins. Homology modeling is used to predict the structure of an unknown protein from existing homologous proteins. One example of this is hemoglobin in humans and the hemoglobin in legumes (leghemoglobin), which are distant relatives from the same protein superfamily. Both serve the same purpose of transporting oxygen in the organism. Although both of these proteins have very different amino acid sequences, their protein structures are very similar, reflecting their shared function and shared ancestor. Other techniques for predicting protein structure include protein threading and de novo (from scratch) physics-based modeling. Another aspect of structural bioinformatics include the use of protein structures for Virtual Screening models such as Quantitative Structure-Activity Relationship models and proteochemometric models (PCM). Furthermore, a protein's crystal structure can be used in simulation of for example ligand-binding studies and in silico mutagenesis studies.
1852: Ingouville and parts of Graville-l'Eure and Sanvic 1919: all of Graville-Sainte-Honorine 1953: Bleville 1955: all of Sanvic 1971: part of Harfleur (a district of Caucriauville) 1973: Rouelles (with the status of associated commune, 3,184 inhabitants in 2006)
=== Stress-responsive kinases === Kinases that regulate p53 phosphorylation can be divided into two broad groups. One group includes members of the MAPK pathways, including JNK1–3, ERK1/2 and p38 MAPK, which are activated by diverse cellular stresses such as oxidative stress and heat shock. A second group comprises DNA damage response kinases, including ATM, ATR and DNA-PK, together with downstream checkpoint kinases such as CHK1 and CHK2, which are activated by DNA damage and replication stress and contribute to p53 regulation through phosphorylation-dependent signalling. Additional kinases implicated in p53 phosphorylation include the CDK-activating kinase (CAK; CDK7–cyclin H–MAT1), which has been shown to phosphorylate p53 (for example at Ser33) in vitro and in vivo, and TP53RK (PRPK), which has been reported to phosphorylate p53 at Ser15. Oncogene-induced activation of p53 can also occur via p14ARF (ARF), which inhibits the p53 antagonist MDM2 and thereby stabilizes p53.
Sources: en.wikipedia.org
=== Interactions === There were eight interactions identified by Mentha. The first one was UFSP2 which hydrolyzes the peptide bond at the C-term gly of UFM1, a ubiquitin-like modifier protein bound to a number of target proteins. The second one was HSCB which acts as a co-chaperone in iron-sulfur cluster assembly in mitochondria. The third was GRB2 which is an adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway. The fourth was CYLD which is a protease that cleaves Lys-63-linked polyubiquitin chains, controls regulation of cell survival, proliferation, and differentiation, and is required for normal cell cycle progress. The fifth was ATM which activates checkpoint signaling upon double strand breaks, apoptosis, and genotoxic stress. The sixth was FAM177A1, the function of which is unknown. The last two were THID2 and Q81kP6 which are both in bacillus anthracis.
=== Direct intensity === This method adds to the dilution to threshold method by considering the perceived intensity of the compounds as well. Assessors can report this based on a predetermined scale. The posterior intensity method measures the maximum intensity perceived for each eluting compound. A panel of assessors is recommended to be used to obtain an averaged signal. On the other hand, the dynamic time-intensity method measures the intensity at different points in time starting from the time of elution, allowing a continuous measurement of onset, maximum, and decline of the odour intensity. This is used in the Osme (Greek word for odour) method developed in 1992 by Da Silva. An aromagram can then be constructed in a similar way as an FID chromatogram whereby intensity is plotted as a function of retention time. The peak height corresponds to the maximum intensity perceived whereas the peak width corresponds to the duration of the odour perceived. The time requirement maybe high for this particular method regarding the essentials of assessor training, as lack of training may result in inconsistencies in scale usage. However, with a trained panel of assessors, the analysis can be done in a relatively short amount of time with high precision.
Traditionally, Parkinson's disease has been considered a non-genetic disorder. However, between 15 and 25% of people with PD report familial connections who have PD, and from 10 to 20% have a first-degree relative with PD. No single-gene mutation in PD causes PD, but multiple genetic factors can increase susceptibility and the risk of developing either familial or sporadic PD. More penetrant PD mutations with a higher risk of developing the disease, tend to be rare but are often associated with familial PD (e.g. rare SNCA variants). A second group of variants (including GBA and LRRK2 variants) are uncommon and carry an intermediate level of risk in a significant minority of PD cases. A third group of genetic variants occur often but carry low risk. Unequivocal links to PD pathogenesis have been found for mutations in at least six genes: LRRK2, SNCA, and VPS35 (dominant forms) and PRKN/Parkin, PINK1, and PARK7/DJ1 (recessive forms). The most extensively studied PD-related genes are LRRK2 and SNCA. At least 16 genes display "causal" variants associated with genetic predisposition for PD, through higher familial inheritance of PD or development of early-onset PD symptoms. An additional 44 novel risk loci have been associated with sporadic PD. Both autosomal dominant and autosomal recessive gene mutations have been implicated in the development of PD. Autosomal dominant genes include SNCA (PARK1, PARK4, NCAP) and VPS35 (PARK17, MEM3), which are rare but highly penetrant, and CHCHD2. LRRK2 (PARK8, DARDARIN) and GBA (GBA1) are pathogenic but have variable penetrance.
== Release history == Reek of Putrefaction was first released in 1988. When released, Reek of Putrefaction reached No. 6 on the UK Indie Chart, establishing Carcass' earlier grindcore sound. The late BBC Radio 1 DJ John Peel declared it his favourite album of 1988, in an interview for British newspaper The Observer. Reek of Putrefaction was re-released in 1994. In 2002, the album was reissued. The album was re-released in 2008 as part of an ongoing series of Carcass reissues to tie in with their reunion. The main album, along with the demo Flesh Ripping Sonic Torment, is presented as one side of a dualdisc, while the DVD side features the first part of an extended documentary titled The Pathologist's Report Part I: Incubation. Later editions contain the album on a CD and the documentary on a separate DVD. The album is presented in a 12-panel digipak with full lyrics and artwork and is sealed in a white medical bag with sticker, to hide the controversial cover art.
== Products == Many products such as red meat, seafood, minimally processed fruits and vegetables, salads, pasta, cheese, bakery goods, poultry, cooked and cured meats, ready meals and dried foods are packaged under MA. A summary of optimal gas mixtures for MA products is shown in the following table. Modified atmosphere packaging for different food products and optimal gas mixtures
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.